Topics

Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors

03:41 EDT 28 Oct 2019 | FinanzNachrichten

Lund Sweden, October 28 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and NeoTX announce that the dosing of the first patient in its Phase 1b trial of naptumomab estafenatox (naptumomab, ANYARA) ...

Related Biotechnology, Pharmaceutical and Healthcare News

Original Article: Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors

NEXT ARTICLE

More From BioPortfolio on "Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches

BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored ND2A Group with offices at 677 Craig Rd, Suite 216, Creve Coeur, Missouri 63141 USA. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters here: Contact ND2A Group.

All rights reserved. All other trademarks recognized. Copyright © 2019 ND2A Group. Site developed by Alacrify Ltd

.